This Antibody was verified by IP Mass Spectrometry to ensure that the antibody binds to the antigen stated. View Details
MA5-14260 targets p14ARF/p16beta in ICC/IF, IP, and WB applications and shows reactivity with Human samples.
The MA5-14260 immunogen is recombinant p14ARF protein.
The INK4a-ARF locus encodes two unrelated proteins both of which function in tumor suppression. p14ARF arrests the cell cycle in a p53-dependent manner. p14ARF binds to mdm2 and promotes the rapid degradation of mdm2 proteinrequired for mdm2 modification and concurrent p53 stabilization and accumulation. This interaction is mediated by the exon 1beta-encoded N-terminal domain of p14ARF and a C-terminal region of mdm2. Deletion of the ARF-INK4a locus simultaneously impairs both the INK4a-cyclin D/cdk4-RB and the ARF-mdm2-p53 pathways.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Alternative reading frame; ARF; CDK4 inhibitor p16-INK4; CDK4I; cell cycle negative regulator beta; Cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); MTS-1; Multiple tumor suppressor 1; p14ARF; p16-INK4; p16-INK4a; Tumor suppressor ARF
Gene Aliases: ARF; CDK4I; CDKN2; CDKN2A; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4; P16INK4A; P19; P19ARF; TP16
UniProt ID: (Human) Q8N726
Entrez Gene ID: (Human) 1029